Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +76.67% and +17.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
T Stamp Inc. (IDAI) delivered earnings and revenue surprises of -55.56% and -22.09%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
NextNRG Inc. (NXXT) delivered earnings and revenue surprises of +1.71% and -4.90%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Cloudastructure Inc. (CSAI) delivered earnings and revenue surprises of -189.70% and -38.19%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +82.76% and -14.15%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
The Q3 earnings cycle continues to wind down, with this week's reporting docket featuring several retail heavyweights, including Walmart (WMT), Target (TGT), and Home Depot (HD).
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +16.67% and -47.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
PagSeguro Digital (PAGS) delivered earnings and revenue surprises of +4.88% and -0.63%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Envela (ELA) delivered earnings and revenue surprises of +7.14% and -16.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Barfresh Food Group (BRFH) delivered earnings and revenue surprises of +83.33% and -12.65%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Red Cat (RCAT) delivered earnings and revenue surprises of -30.00% and -69.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Kyntra Bio (KYNB) delivered earnings and revenue surprises of +6.56% and -10.38%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?